Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.47 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21268531 | 0.88 | DGAT1 (0.54) | DGAT1NPC1RAB9AGAAALDH1A1 | |
| SCHEMBL2671322 | 0.85 | GAA (0.56) | DGAT1NPC1RAB9AGAAALDH1A1 | |
| SCHEMBL27007857 | 0.85 | DGAT1 (0.63) | DGAT1NPC1RAB9AGAAALDH1A1 | |
| SCHEMBL13485811 | 0.85 | DGAT1 (0.63) | DGAT1NPC1RAB9AGAAALDH1A1 | |
| SCHEMBL793201 | 0.81 | DGAT1 (0.65) | DGAT1NPC1RAB9AGAAALDH1A1 | |
| SCHEMBL909599 | 0.81 | CES2 (0.61) | NPC1RAB9AGAAALDH1A1LMNA | |
| SCHEMBL3345916 | 0.81 | DGAT1 (0.54) | DGAT1NPC1RAB9AGAAALDH1A1 | |
| SCHEMBL506513 | 0.81 | DGAT1 (0.54) | DGAT1NPC1RAB9AGAAALDH1A1 | |
| SCHEMBL3346723 | 0.81 | DGAT1 (0.54) | DGAT1NPC1RAB9AGAAALDH1A1 | |
| SCHEMBL2921979 | 0.80 | TMEM97 (0.56) | DGAT1NPC1RAB9AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820218-B | Preparation method of apatamide and intermediate | 江苏希迪制药有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-118420541-A | Preparation method of enzae Lu An | 山东新时代药业有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-117820218-A | Preparation method of apatamide and intermediate | 江苏希迪制药有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-113896732-B | Preparation method and application of anticancer drug carbamatinib | 沈阳红旗制药有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-115197084-A | Preparation method of enzalutamide key intermediate | 中国船舶重工集团公司第七一八研究所 | 2022-10-18 | — | — | CN | claimed |
| CN-112645880-B | Synthetic method of enzalutamide | 山东铂源药业股份有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-107501237-B | Synthetic method of Apalutamide | 上海西浦医药科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-113896732-A | Preparation method and application of anti-cancer drug carbamatinib | 沈阳红旗制药有限公司 | 2022-01-07 | — | — | CN | claimed |
| CN-112645880-A | Synthetic method of enzalutamide | 山东铂源药业有限公司 | 2021-04-13 | — | — | CN | claimed |
| EP-2963026-B1 | SUBSTITUTED (R)-3-(4-METHYLCARBAMOYL-3-FLUOROPHENYLAMINO)TETRAHYDROFURAN-3-ENECARBOXYLIC ACID (VARIANTS) AND ESTER THEREOF, METHOD FOR PRODUCING AND USING SAME | R PHARM INT LLC (RU) | 2020-04-29 | — | — | EP | claimed |
| CN-110872258-A | Preparation process of prostate cancer drug enzalutamide | 北京凯莱天成医药科技有限公司 | 2020-03-10 | — | — | CN | claimed |
| US-20160016925-A1 | Substituted (R)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-encarboxylic acid (variants) and ester thereof, method for preparation and use | Ivachtchenko, Alexandre Vasilievich (US) | 2016-01-21 | — | — | US | claimed |
| EP-2963026-A2 | SUBSTITUTED (R)-3-(4-METHYLCARBAMOYL-3-FLUOROPHENYLAMINO)TETRAHYDROFURAN-3-ENECARBOXYLIC ACID (VARIANTS) AND ESTER THEREOF, METHOD FOR PRODUCING AND USING SAME | Limited Liability Company "Avionco" (RU) | 2016-01-06 | — | — | EP | claimed |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| CN-101048369-A | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016925-A1 | Substituted (R)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-encarboxylic acid (variants) and ester thereof, method for preparation and use | AR, SRD5A1, CYP19A1 | DGAT1 1656/4885NPC1 588/4885RAB9A 3972/4885 |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | DGAT1 2039/4885NPC1 533/4885RAB9A 1267/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | DGAT1 3125/4885NPC1 202/4885RAB9A 2194/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | DGAT1 486/4885NPC1 110/4885RAB9A 3188/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | DGAT1 486/4885NPC1 110/4885RAB9A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.